Published in Neoplasia on April 07, 2017
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008) 5.85
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res (1997) 3.98
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA (1995) 3.83
Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst (1999) 3.22
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol (2005) 3.06
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal (2010) 2.27
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol (2008) 1.88
Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs (1995) 1.82
Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst (1997) 1.68
Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A (2014) 1.62
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther (2012) 1.57
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer (2004) 1.57
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer (1999) 1.48
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care (2012) 1.42
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res (2014) 1.34
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res (2013) 1.15
Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1.13
Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat (2007) 1.09
Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget (2014) 0.96
Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol (2002) 0.88
Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis (2016) 0.78